1-20 of 66
James G. Christensen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Abstract 3880: Functional dissection of the highly plastic basal cell state in pancreatic cancer

Anupriya Singhal, Hannah Styers, Jonathan Rub, Kate Ryan, Jung Yun Kim, Zeynep C. Tarcan, Jill Hallin, Olca Basturk, Rona Yaeger, James G. Christensen, Yan Yan, Elisa de Stanchina, Tuomas Tammela
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3880.
https://doi.org/10.1158/1538-7445.AM2025-3880
Published: 21 April 2025
View articletitled, Abstract 3880: Functional dissection of the highly plastic basal cell state in pancreatic cancer
Journal Articles

Abstract 3786: Combination of MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors for the treatment of MTAP-deleted KRAS-mutant pancreatic cancer

Kristina Drizyte-Miller, Lars D. Engstrom, Jeffrey A. Klomp, Clint A. Stalnecker, Laura Waters, Andrew Calinisan, Ryan Robb, Khalilah E. Taylor, Mallory K. Roach, Addison G. Stamey, Seamus Degan, Wen-Hsuan Chang, Xousaen M. Helu, David Nguyen, Laura D. Hover, Elisa Baldelli, Mariaelena Pierobon, Emanuel F. Petricoin, Kirsten L. Bryant, David M. Briere, James G. Christensen, Jill Hallin, Adrienne D. Cox, Peter Olson, Channing J. Der
Journal: Cancer Research
Cancer Res (2025) 85 (8_Supplement_1): 3786.
https://doi.org/10.1158/1538-7445.AM2025-3786
Published: 21 April 2025
View articletitled, Abstract 3786: Combination of MTA-cooperative PRMT5 inhibitor BMS-986504 and KRAS inhibitors for the treatment of MTAP-deleted KRAS-mutant pancreatic cancer
Journal Articles

Abstract C077: Functional Dissection of the Highly Plastic Basal Cell State in Pancreatic Cancer

Anupriya Singhal, Hannah C. Styers, Jonathan Rub, Zhuxuan Li, Zeynep Tarcan, Jill Hallin, Olca Basturk, Rona Yaeger, James G. Christensen, Doron Betel, Yan Yan, Elisa de Stanchina, Tuomas Tammela
Journal: Cancer Research
Cancer Res (2024) 84 (17_Supplement_2): C077.
https://doi.org/10.1158/1538-7445.PANCREATIC24-C077
Published: 15 September 2024
View articletitled, Abstract C077: Functional Dissection of the Highly Plastic Basal Cell State in Pancreatic Cancer
Journal Articles

Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer

Matthew A. Marx, Aaron C. Burns, Nidhi Arora, Thomas P. Bobinski, David M. Briere, Andrew Calinisan, Robin J. Gunn, John M. Ketcham, David Lawson, Matthew Lee, Peter Olson, Christopher R. Smith, Niranjan Sudhakar, James G. Christensen, Chelsea X. Chen, Natalie Yuen, Livia Ulicna, Frank Duong, Christophe Colas, Anjana Ramnath, Ron Xu, Edna Chow Maneval, Pratik S. Multani, Rupal Patel, Archana Kumar, Anneleen Daemen, Anthony Romero, Melissa R. Junttila, Lori S. Friedman
Journal: Cancer Research
Cancer Res (2024) 84 (7_Supplement): ND04.
https://doi.org/10.1158/1538-7445.AM2024-ND04
Published: 05 April 2024
View articletitled, Abstract ND04: Discovery of ORIC-944, a novel inhibitor of PRC2 with best-in-class properties for the treatment of prostate cancer
Journal Articles

Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers

Laura Waters, Ruth Aranda, Xousaen Helu, Laura Vegar, Krystal Moya, Andrew Calinisan, Allan Hebbert, Jill Hallin, Darin Vanderpool, David M. Briere, James G. Christensen, Peter A. Olson, Lars D. Engstrom
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 3319.
https://doi.org/10.1158/1538-7445.AM2024-3319
Published: 22 March 2024
View articletitled, Abstract 3319: The MTA-cooperative PRMT5 inhibitor, MRTX1719, demonstrates increased anti-tumor activity in combination with KRAS mutant-selective inhibitors in MTAP del,KRAS-mutant cancers
Journal Articles

Abstract 7268: The SOS1 inhibitor MRTX0902 demonstrates activity across cancer models with mutations in proximal components of the RAS-MAPK pathway

Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Jade Laguer, David Briere, Allan Hebbert, Andrew Calinisan, Silvia Coma, Jonathan Pachter, James G. Christensen, Peter Olson, Shilpi Khare
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 7268.
https://doi.org/10.1158/1538-7445.AM2024-7268
Published: 22 March 2024
View articletitled, Abstract 7268: The SOS1 inhibitor MRTX0902 demonstrates activity across cancer models with mutations in proximal components of the RAS-MAPK pathway
Journal Articles

Abstract 4448: Effects of adagrasib on cholesterol, lipid and glucose gene expression regulation in tumor xenograft models and patient samples

Fabiola Shelton, Natalie Hoffman, David Trinh, Xousaen M. Helu, Andrew Calinisan, Allan Hebbert, Larry Yan, David M. Briere, Laura Hover, Julio Fernandez-Benet, Kenna Anderes, James G. Christensen, Jill Hallin, Peter Olson
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 4448.
https://doi.org/10.1158/1538-7445.AM2024-4448
Published: 22 March 2024
View articletitled, Abstract 4448: Effects of adagrasib on cholesterol, lipid and glucose gene expression regulation in tumor xenograft models and patient samples
Journal Articles

Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models

Anneleen Daemen, Natalie Yuen, Amber Wang, Aleksandr Pankov, Livia Ulicna, Chelsea Chen, Frank L. Duong, Jason Long, Matthew A. Marx, James G. Christensen, Lori S. Friedman, Melissa R. Junttila
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 6586.
https://doi.org/10.1158/1538-7445.AM2024-6586
Published: 22 March 2024
View articletitled, Abstract 6586: ORIC-944, a potent and selective allosteric PRC2 inhibitor with best-in-class properties, demonstrates combination synergy with AR pathway inhibitors in prostate cancer models
Journal Articles

Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models

Xousaen M. Helu, Ellie Griffiths, Andrew Calinisan, Allan Hebbert, Larry Yan, Natalie Hoffman, David Trinh, Laura Hover, Julio Fernandez-Banet, David M. Briere, Ella Lifset, Peter Olson, James G. Christensen, Jill Hallin
Journal: Cancer Research
Cancer Res (2024) 84 (6_Supplement): 1943.
https://doi.org/10.1158/1538-7445.AM2024-1943
Published: 22 March 2024
View articletitled, Abstract 1943: Discovery and characterization of potential drivers of resistance to the KRAS G12D inhibitor, MRTX1133, in cancer cell line models
Journal Articles

TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors

A. Cole Edwards, Clint A. Stalnecker, Alexis Jean Morales, Khalilah E. Taylor, Jennifer E. Klomp, Jeffrey A. Klomp, Andrew M. Waters, Niranjan Sudhakar, Jill Hallin, Tracy T. Tang, Peter Olson, Leonard Post, James G. Christensen, Adrienne D. Cox, Channing J. Der
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4112–4129.
https://doi.org/10.1158/0008-5472.CAN-23-2994
Published: 15 December 2023
View articletitled, TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors
Open the PDF for TEAD Inhibition Overcomes YAP1/TAZ-Driven Primary and Acquired Resistance to KRASG12C Inhibitors in another window
Includes: Supplementary data
Journal Articles

Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy

Suman Mukhopadhyay, Hsin-Yi Huang, Ziyan Lin, Michela Ranieri, Shuai Li, Soumyadip Sahu, Yingzhuo Liu, Yi Ban, Kayla Guidry, Hai Hu, Alfonso Lopez, Fiona Sherman, Yi Jer Tan, Yeuan Ting Lee, Amanda P. Armstrong, Igor Dolgalev, Priyanka Sahu, Tinghu Zhang, Wenchao Lu, Nathanael S. Gray, James G. Christensen, Tracy T. Tang, Vamsidhar Velcheti, Alireza Khodadadi-Jamayran, Kwok-Kin Wong, Benjamin G. Neel
Journal: Cancer Research
Cancer Res (2023) 83 (24): 4095–4111.
https://doi.org/10.1158/0008-5472.CAN-23-2729
Published: 15 December 2023
View articletitled, Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy
Open the PDF for Genome-Wide CRISPR Screens Identify Multiple Synthetic Lethal Targets That Enhance KRASG12C Inhibitor Efficacy in another window
Includes: Supplementary data
Journal Articles

Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers

Laura Vegar, Ruth Aranda, Laura Waters, Krystal Moya, Allan Hebbert, Christopher S. Smith, Jill Hallin, Briere M. David, Lars D. Engstrom, Darin Vanderpool, Matthew M. Marx, James G. Christensen, Peter A. Olson
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2778.
https://doi.org/10.1158/1538-7445.AM2023-2778
Published: 04 April 2023
View articletitled, Abstract 2778: A novel MTA-cooperative PRMT5 inhibitor, MRTX1719, stabilizes the ternary MTA-PRMT5 complex and leads to synthetic lethality in MTAP deleted cancers
Journal Articles

Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC

Shilpi Khare, Niranjan Sudhakar, Jade Laguer, David M. Briere, Larry Yan, Allan Hebbert, Andrew Calinisan, Lars D. Engstrom, Fadia Qiryaqos, Peter Olson, James G. Christensen, Jacob R. Haling
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 3499.
https://doi.org/10.1158/1538-7445.AM2023-3499
Published: 04 April 2023
View articletitled, Abstract 3499: Inhibition of SOS1 by MRTX0902 augments the anti-tumor response of the targeted EGFR inhibitor osimertinib in NSCLC
Journal Articles

Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers

Laura Waters, Ruth Aranda, Krystal Moya, Victoria Bowcut, David Trinh, Allan Hebbert, Leo He, Laura D. Hover, Julio Fernandez-Banet, Jill Hallin, David M. Briere, James G. Christensen, Peter A. Olson, Lars D. Engstrom
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 2779.
https://doi.org/10.1158/1538-7445.AM2023-2779
Published: 04 April 2023
View articletitled, Abstract 2779: Identification of mechanism-based combination targets effective with the MTA-cooperative PRMT5 inhibitor MRTX1719 for the treatment of MTAP deleted cancers
Journal Articles

Abstract 6394: Immune mechanisms underlie full therapeutic efficacy of a novel inhibitor of KrasG12D in mouse models of pancreatic ductal adenocarcinoma

Noah Cheng, Samantha B. Kemp, Nune Markosyan, Rina Sor, Il-Kyu Kim, Jill Hallin, Jason Shoush, Liz Quinones, Natalie V. Brown, Jared B. Bassett, Nikhil Joshi, Salina Yuan, Molly Smith, William P. Vostrejs, Kia Z. Perez-Vale, Benjamin Kahn, Feiyan Mo, Timothy R. Donahue, Caius G. Radu, Cynthia Clendenin, James G. Christensen, Robert H. Vonderheide, Ben Z. Stanger
Journal: Cancer Research
Cancer Res (2023) 83 (7_Supplement): 6394.
https://doi.org/10.1158/1538-7445.AM2023-6394
Published: 04 April 2023
View articletitled, Abstract 6394: Immune mechanisms underlie full therapeutic efficacy of a novel inhibitor of KrasG12D in mouse models of pancreatic ductal adenocarcinoma
Journal Articles

Abstract 1841: MRTX849 inhibits P-gp and demonstrates CNS exposure in mouse models and cancer patients and demonstrates antitumor activity in intracranial mouse models of lung cancer brain metastasis

Kazuhide Shimizu, Jill Hallin, Mohini Singh, Naema Nayyar, Matthew R. Strickland, Aaron C. Burns, Cornelius Cilliers, Lauren Hargis, Peter A. Olson, Matthew A. Marx, Priscilla K. Brastianos, Hiroaki Wakimoto, James G. Christensen
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1841.
https://doi.org/10.1158/1538-7445.AM2022-1841
Published: 15 June 2022
View articletitled, Abstract 1841: MRTX849 inhibits P-gp and demonstrates CNS exposure in mouse models and cancer patients and demonstrates antitumor activity in intracranial mouse models of lung cancer brain metastasis
Journal Articles

Abstract LB505: Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor

John M. Ketcham, David M. Briere, Aaron C. Burns, James G. Christensen, Robin J. Gunn, Jacob Haling, Anthony Ivetac, Shilpi Khare, Jon Kuehler, Svitlana Kulyk, Jade Laguer, John D. Lawson, Krystal Moya, Natalie Nguyen, Peter Olson, Lisa Rahbaek, Christopher R. Smith, Niranjan Sudhakar, Nicole C. Thomas, Darin Vanderpool, Xiaolun Wang, Matthew A. Marx
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB505.
https://doi.org/10.1158/1538-7445.AM2022-LB505
Published: 15 June 2022
View articletitled, Abstract LB505: Design and discovery of MRTX0902, a potent, selective, and orally bioavailable SOS1 inhibitor
Journal Articles

Abstract LB193: Chemical genomics identify novel druggable nodes and resistance pathways in the presence of concomitant SOS1 and KRAS inhibition

Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Lars D. Engstrom, Jade Laguer, James Medwid, Laura Vegar, Darin Vanderpool, Matthew A. Marx, John M. Ketcham, James G. Christensen, Peter Olson, Jacob R. Haling
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): LB193.
https://doi.org/10.1158/1538-7445.AM2022-LB193
Published: 15 June 2022
View articletitled, Abstract LB193: Chemical genomics identify novel druggable nodes and resistance pathways in the presence of concomitant SOS1 and KRAS inhibition
Journal Articles

Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D-mutant models

Vickie Bowcut, Andrew Calinisan, David M. Briere, Lauren Hargis, Lars D. Engstrom, Jade Laguer, Darin Vanderpool, Xiaolun Wang, J David Lawson, Nicole Thomas, Robin Gunn, Christopher R. Smith, Julio Fernandez-Banet, Leo He, Adam Pavlicek, Lisa Rahbaek, Matthew A. Marx, Peter Olson, James G. Christensen, Jill Hallin
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): 1131.
https://doi.org/10.1158/1538-7445.AM2022-1131
Published: 15 June 2022
View articletitled, Abstract 1131: Pharmacogenomic insight into targetable vulnerabilities and modifiers of response to MRTX1133 in KRASG12D-mutant models
Journal Articles

Abstract ND02: MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers

John M. Ketcham, Shilpi Khare, Niranjan Sudhakar, David M. Briere, Larry Yan, Jade Laguer, Laura Vegar, Darin Vanderpool, Jill Hallin, Lauren Hargis, Vickie Bowcut, David Lawson, Robin J. Gunn, Anthony Ivetac, Nicole C. Thomas, Barbara Saechao, Natalie Nguyen, Jeffrey Clarine, Lisa Rahbaek, Christopher R. Smith, Aaron C. Burns, Matthew A. Marx, James G. Christensen, Peter Olson, Jacob R. Haling
Journal: Cancer Research
Cancer Res (2022) 82 (12_Supplement): ND02.
https://doi.org/10.1158/1538-7445.AM2022-ND02
Published: 15 June 2022
View articletitled, Abstract ND02: MRTX0902: A SOS1 inhibitor for therapeutic intervention of KRAS-driven cancers